Medical Device News

Aegea Biotechnologies Advances to Semi-Finals of the $5M XPRIZE Rapid COVID Testing Competition

Aegea Biotechnologies' New, Highly Sensitive PCR-based COVID-19 Assay Utilizing Patented Switch-Blocker Technology Advances in the Global XPRIZE Competition Seeking "Faster, Cheaper, and Easier-to-Use COVID-19 Testing Methods at Scale"

About Medical Device News Magazine

About Medical Device News Magazine. We are a digital publication founded in 2008 located in the United States.

Advertise with Medical Device News Magazine! Join Our #1 Family of Advertisers!

We pride ourselves on being the best-kept secret when it comes to distributing your news! Our unique digital approach enables us to circulate your...

September 14, 2020

Aegea Biotechnologies, Inc. a biotechnology company focusing on the development and commercialization of next-generation nucleic acid and clinical diagnostic technologies, announces that it has been selected as a semi-finalist in the prestigious XPRIZE competition for rapid COVID testing.

Aegea Biotechnologies notes XPRIZE is renowned for its worldwide competitions to solve humanity’s most important challenges. The $5 million, XPRIZE Rapid COVID Testing competition was launched this summer to accelerate the development of high-quality COVID-19 testing that is affordable, easy to use, and that has a fast turnaround time.  These improved COVID-19 tests would enable more frequent testing.  A goal of the XPRIZE Rapid COVID Testing competition is to increase the scale of COVID-19 testing capabilities by a hundredfold over our current standard, in order to more safely return to everyday activities.  Approximately 700 teams spanning six continents registered for the XPRIZE Rapid COVID Testing competition.

Aegea advanced to the XPRIZE Rapid COVID Testing Semi-Finals after sharing results of a new, highly sensitive, quantitative PCR-based assay for detecting SARS-CoV-2 (COVID-19 virus) that Aegea designed and is developing and validating clinically in collaboration with Biocept, Inc.  The COVID-19 PCR assay utilizes Switch-Blocker technology, which is patent protected in the United States and in 10 major international territories and is jointly owned by Aegea and Biocept. Under an associated cross-license agreement, Aegea has exclusive rights in the field of infectious disease, and Biocept has certain rights within the field of clinical oncology, where Biocept has used the technology to identify and report rare cancer-associated mutations in more than 20,000 cancer patients to aid medical treatment decisions.

In addition to high sensitivity and specificity, affordability and fast turnaround time, Aegea’s test is designed to provide additional information on specific strain types of SARS-CoV-2.

“We are pleased to compete for the XPRIZE and to put our inventions and ideas towards solving an urgent global health need.  Aegea’s new COVID-19 test utilizes the single nucleotide discrimination capacities of the patented Switch-Blocker technology to differentiate itself from other COVID-19 PCR assays,” said Lyle J. Arnold, Ph.D., Founder & CEO of Aegea.  “Our assay is designed to detect low copy numbers of viral RNA, therefore it could potentially detect the viral load at lower levels than other PCR-based assays.  This could be enormously helpful in reducing the infection rate because it has been reported that asymptomatic patients are able to infect others.  At the same time, due to its high sensitivity, our assay should allow multiple patient samples to be pooled into a single assay, to greatly speed up the number of patients tested. Additionally, our COVID-19 PCR assay is designed with the ability to identify high-risk and low-risk strains of SARS-CoV-2, which could significantly aid medical decision-making, for identifying patients most in need of hospitalization. It also distinguishes SARS-CoV-2, which is associated with COVID-19, from other common forms of the SARS virus.”

Aegea Biotechnologies Chief Business Officer, Stella M. Sung, Ph.D., adds, “In addition to applying proprietary science, Aegea has established strategic collaborations that will enable us to quickly scale and commercialize our COVID-19 PCR test. Biocept, has a CLIA-certified, CAP-accredited high-complexity molecular lab, and has the ability to run our high throughput, multiplexed assays. Biocept also has a right of first negotiation for use of the assay in its clinical laboratory. Separately, Tauriga Sciences (OTC/QB: TAUG) has extensive relationships with manufacturers and distributors to help with supply chain issues and commercial opportunities. Being a semi-finalist for the XPRIZE will further accelerate Aegea’s development and commercialization timelines. Our immediate goal is to get a fast, accurate, affordable, accessible, information-rich test to the market.  Our long-term purpose is to equip our global community with a powerful tool for managing pandemics and for saving lives.”

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

Other News

Ultrahuman Announces its App Store ‘PowerPlugs’ with the World’s First AFib Detection Technology on a Smart Ring

Recognizing each individual’s health journey is unique, PowerPlugs enable people to choose and focus on the aspects of their health that matter most. It’s designed for highly personalized health insights, ensuring that every individual can personalize their health tracking to their unique needs and goals.

VisionAir Solutions Celebrates Milestone and New Collaboration

This achievement marks VisionAir Solutions commitment to bringing technological innovation to pulmonary medicine. Since its acquisition by Theken Companies last year, VAS has over doubled its growth and continues to demonstrate industry adoption and the advantages of personalized healthcare.

Valencia Technologies Announces CMS Publication of 2025 Medicare Proposed Rule for eCoin® Procedure

Ann Decker, VP of Reimbursement for Valencia Technologies, stated, "The cumulative effect of the proposed 2025 continuation of APC assignment 5464, the improved ASC payment rate, and the recognition of ITNS as a minimally invasive OAB treatment option in the recently updated guidelines by the American Urological Association (AUA) and the Society of Urodynamics, Female Pelvic Medicine, and Urogenital Reconstruction (SUFU), underscores that the eCoin ITNS system will have a strong reimbursement pathway throughout 2025 and beyond.